Dr Braun on Frontline Nivolumab Monotherapy Followed by Salv

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Related Keywords

Davida Braun , Alfred Gilman Yale , Louis Goodman , Braun , Yale School Of Medicine , Yale Cancer Center , Medical Oncology , Alfred Gilman Yale Scholar , Smilow Cancer Hospital , Yale School , Onclive Tv , Genitourinary Cancers ,